Rationale: Synthetic adrenocorticotropic hormone (Tetracosactide) has been used in the treatment of refractory glomerular diseases. Literature surrounding the use of this medication is limited to small case series and there is conflicting data on the rate of adverse events associated with this medication.
Presenting Concerns Of The Patient: Glomerulonephritis not in remission after at least 6 months of treatment with conservative care. Stable doses of concurrent immunosuppression were permitted.
Diagnoses: Membranous nephropathy, IgA nephropathy, minimal change disease, and focal and segmental glomerulosclerosis.
Intervention: Intramuscular synthetic adrenocorticotropic hormone (Tetracosactide, Synacthen Depot) with doses of either 1 mg weekly or 1 mg twice weekly.
Outcomes: Five of 12 patients had at least a partial remission with Tetracosactide. Median time to response was 6 months for responders. Five of the 12 patients had adverse events documented, 2 of which led to treatment discontinuation. No patients with focal and segmental glomerulosclerosis responded to treatment.
Lessons Learned: Higher rate of adverse events than previously reported with synthetic adrenocorticotropic hormone and uncertain treatment efficacy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744192 | PMC |
| http://dx.doi.org/10.1177/20543581211066979 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prenatal exposure to synthetic chemicals in relation to HPA axis activity: A systematic review of the epidemiological literature.
Sci Total Environ
December 2024
Environmental and Occupational Health Sciences Institute, Rutgers University, Piscataway, NJ 08854, USA; Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ 08854, USA. Electronic address:
Background: Pregnant people are widely exposed to numerous synthetic chemicals with known endocrine-disrupting properties (e.g., phthalates, phenols, per- and poly-fluoroalkyl substances (PFAS)).
View Article and Find Full Text PDFAntidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress.
Eur J Pharmacol
December 2024
National Research Center "Kurchatov Institute", Moscow, Russia; Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia. Electronic address:
Current antidepressant therapy shows substantial limitations, and there is an urgent need for the development of new treatment strategies for depression. Stressful events and hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis play an important role in the pathogenesis of depression. HPA axis activity is self-regulated by negative feedback at several levels including adrenocorticotropic hormone (ACTH)-mediated feedback.
View Article and Find Full Text PDFChanges of Transcriptomic Activity in Rat Brain Cells under the Influence of Synthetic Adrenocorticotropic Hormone-Like Peptides.
Biochemistry (Mosc)
September 2024
National Research Centre "Kurchatov Institute", Moscow, 123182, Russia.
Synthetic peptides have a wide range of clinical effects. Of particular interest are peptides based on adrenocorticotropic hormone (ACTH) both as already used and as potential drugs for preventing consequences of cerebral ischemia. However, it is necessary to study influence of the peptide on the brain cells under normal physiological conditions, including understanding the risks of their use.
View Article and Find Full Text PDFHypoadrenocorticism in cats: a 40-year update.
J Feline Med Surg
September 2024
The Royal (Dick) School of Veterinary Studies and The Roslin Institute, The University of Edinburgh, Easter Bush Veterinary Campus, Midlothian, Roslin, UK.
Article Synopsis
- Addison's disease in cats is extremely rare, with only about 40 cases recorded since 1983, making it a significant clinical challenge.
- Unlike dogs, where hypoadrenocorticism is well understood, diagnosing the condition in cats is difficult due to variable symptoms and the tendency for treatment with corticosteroids to mask the diagnosis.
- Diagnosis requires an ACTH stimulation test, and while treatment is similar to that for dogs involving corticosteroids, the only available mineralocorticoid for cats hasn't been thoroughly tested for safety.
Safety and efficacy assessment of a synthetic porcine recombinant corticotrophin for the ACTH stimulation test in healthy cats.
Domest Anim Endocrinol
October 2024
Veterinary Sciences Post-Graduation Program (PPGCV), Veterinary Faculty, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; Animal Medicine Departament, Veterinary Faculty, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil. Electronic address:
Porcine adrenocorticotrophic hormone (ACTH) has been considered valid for the ACTH stimulation test (ACTHST) in humans and dogs; however, its safety and efficacy for use in cats are unknown. Also, the equivalence between 5 µg/kg and 125 µg/cat dose of synthetic corticotropin (1-24 ACTH - cosyntropin/tetracosactide) is assumed for ACTHST in cats. This study evaluated the safety and effectiveness of different porcine recombinant ACTH doses for the ACTHST in healthy cats and its equivalence with tetracosactide.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!